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ABSTRACT 
In gene therapy, the aim is to change the behaviour of a cell by introduction of genetic 
material, often DNA encoding a protein or a therapeutic RNA. The purpose can be to replace 
a malfunctioning copy of a gene, as in clinical trials for treatment of X-linked severe 
combined immunodeficiency, or introduce a new gene into the body to help fight a disease, 
as has been done in clinical trials for e.g. leukaemia and lymphoma where immune cells has 
been modified to recognize and destroy cancer. In order to alter the behaviour, the genetic 
material must be transported into the cell and reach the nucleus. The two main ways to 
achieve this is either using viral vectors, where engineered viruses carry the therapeutic DNA, 
or nonviral vectors, which are commonly based on plasmids produced in bacteria. This thesis 
focuses on nonviral vectors.  
Nonviral vectors are generally considered safer and more easily produced than viral vectors, 
but are less efficient in delivery and long term expression. This is thought to be partly due to 
the plasmid backbone, i.e. sequences needed only for propagation in the bacteria such as 
origin of replication and selection markers, commonly antibiotics resistance genes. 
Bacterially produced DNA sequences have a different methylation pattern than eukaryotic 
DNA. It has been shown that this can induce an immune response, especially in combination 
with the use of lipids for transfection. Also for naked delivery of plasmids, the expression is 
transient, which could be due to epigenetic phenomenon. A way to optimize the plasmid 
vector is to remove the bacterial backbone by recombination in the production bacteria. The 
resulting vector is called the minicircle (MC).  
In one of studies included in this thesis, we investigate how the size of the MC vector affects 
coiling and relate these findings to analysis of other aspects such as robustness, expression 
efficiency and transfection. We find that reducing the size of the MC affects the configuration 
of the vector, causing an increased frequency of dimer and trimer formation during 
production. We also find that there seems to be a lower size limit for efficient expression. 
However, the smaller sizes also result in a vector which is more robust than conventional 
plasmids when exposed to shearing forces, and shows extended expression in vivo. In the two 
other studies, we evaluate the vector for use in muscle. A comparison of the MC to a 
conventional plasmid for expression of a growth factor in heart and skeletal muscle in the 
mouse shows that the smaller size allows for a higher effective dose, and thus, higher gene 
expression. The third study demonstrates that it is possible to use the MC to express small 
regulatory RNAs for splice-switching, targeting Duchenne muscular dystrophy, and that 
treatment with these MCs in mouse muscle results in increased dystrophin levels. However, 
development of suitable delivery methods is required to realize the full potential of MCs in vivo. 
Thus, the smaller size enabling a higher dose, prolonged expression and increased robustness, 
and the fact that the MC construct is devoid of bacterial sequences and antibiotics resistance 
gene make the MC vector an attractive alternative for nonviral gene. However, for use where 
systemic treatment is needed, delivery must be enhanced. Consequently, the vector might be 
more suitable for treatments where only local expression is required, such as single organ 
treatment, DNA vaccination or ex vivo treatments.  
 
  
 
 
 
 
 
POPULÄRVETENSKAPLIG SAMMANFATTNING 
Genterapi syftar till att förändra en cells beteende genom att föra in genetiskt material av 
något slag. Detta kan vara för att ersätta en skadad gen, som i den ärftliga sjukdomen cystisk 
fibros, eller introducera en ny funktion, till exempel för att lära immunceller att känna igen 
cancerceller. För att förändra cellens beteende måste det genetiska materialet transporteras in 
i cellen till kärnan. Ett effektivt sätt att åstadkomma detta är att använda modifierade virus, 
eftersom virus är evolutionärt anpassade till att föra in genetiskt material i andra celler. Det 
finns emellertid problem med dessa så kallade virala vektorer, de kan orsaka immunsvar och 
skador på arvsmassan. Ett alternativ är icke-virala vektorer som ofta baserar sig på plasmid-
DNA producerat och framrenat från bakterier. De är billigare att framställa och säkrare än 
virala vektorer, men har en lägre och mer kortvarig effekt. 
I denna avhandling undersöks ett system för att optimera plasmidbaserade vektorer; göra dem 
effektivare och ännu säkrare genom att ta bort de sekvenser som bara behövs för 
produktionen i bakterier ifrån den färdiga vektorn. Dessa sekvenser verkar bidra till 
immunreaktioner och till att hämma effekten av vektorn över tid. Denna minimerade 
plasmid-vektor för ickeviral genterapi kallas för minicirkel. Minicirkeln undersöks med 
avseende på vad som händer när storleken på plasmiden minskas och utvärderas för 
behandling i muskel.  
Studierna i denna avhandling visar att minicirkeln är en lovande vektor för terapi i muskel. 
Den minskade storleken möjliggör en högre dos och kan också ha en positiv inverkan på 
transporten av vektorn in i cellerna och till kärnan. Försöken visar emellertid också att en 
alltför kort längd på vektorn hämmar genuttrycket. Studierna visar även att transporten av 
vektorn måste optimeras för att uppnå en god effekt i muskelcellerna. Slutligen diskuteras 
olika möjliga framtida användningar av minicirkelsystemet, till exempel som vektor för 
DNA-vaccinering.  
 
    
 
  
 LIST OF SCIENTIFIC PAPERS 
This thesis is based on the following publications, which will be referred to in the text by 
using their Roman numerals:  
I. 
Sofia Stenler, Agneta Andersson, Oscar E. Simonson, Karin E. Lundin,  
Zhi-Ying Chen, Mark A. Kay, C. I. Edvard Smith, Christer Sylvén, and 
Pontus Blomberg, Gene Transfer to Mouse Heart and Skeletal Muscles 
Using a Minicircle Expressing Human Vascular Endothelial Growth 
Factor Journal of Cardiovascular  Pharmacology, 2009;53:18–23 
 
II. 
Sofia Stenler, Oscar P.B. Wiklander, Maria Badal-Tejedor, Janne Turunen, 
Joel Z. Nordin, David Hallengärd, Britta Wahren, Samir EL Andaloussi, 
Mark W. Rutland, C.I. Edvard Smith, Karin E. Lundin and Pontus 
Blomberg, Micro-minicircle Gene Therapy: Implications of Size on 
Fermentation, Complexation, Shearing Resistance, and Expression 
Molecular Therapy - Nucleic Acids, 2014, 3, e140 
 
III. 
Sofia Stenler, Samir. EL Andaloussi, Suzan Hammond, Aurélie 
Goyenvalle, Mark J.A. Wood, Dominic J. Wells, Karin E. Lundin, 
C.I.Edvard Smith and Pontus Blomberg Micro-minicircle vectors for 
splice-switching in Duchenne Muscular Dystrophy Manuscript  
 
 
  
Text from the following paper has been used for writing of the 
Introduction section of this thesis:  
Sofia Stenler, Pontus Blomberg and C.I. Edvard Smith, Safety and efficacy 
of DNA vaccines: plasmids vs. minicircles. Hum Vaccin Immunother. 
2014 May;10(5):1306-8. 
   
  
CONTENTS 
1 Introduction ..................................................................................................................... 7 
1.1 Gene therapy - a brief overview ............................................................................ 7 
1.1.1 Viral vectors .............................................................................................. 7 
1.1.2 Nonviral vectors ........................................................................................ 8 
1.2 Minicircle vectors ................................................................................................ 11 
1.2.1 Systems .................................................................................................... 12 
1.2.2 Characteristics ......................................................................................... 13 
1.2.3 The MC vector for substitution treatment in muscle ............................. 17 
1.2.4 The miMC for snRNA expressing cassettes in muscle .......................... 17 
1.2.5 Other applications ................................................................................... 19 
2 Aim ................................................................................................................................ 23 
3 Methodology.................................................................................................................. 25 
3.1 Constructs and MC production ........................................................................... 25 
3.2 Visualization by Atomic Force Microscopy ....................................................... 26 
3.3 Testing of robustness by pneumatic delivery ..................................................... 27 
3.4 Cell lines and In vitro transfection ...................................................................... 27 
3.4.1 Lipofection .............................................................................................. 27 
3.4.2 Electroporation ........................................................................................ 28 
3.5 In vivo delivery .................................................................................................... 28 
3.5.1 Intramuscular injection ........................................................................... 28 
3.5.2 Hydrodynamic delivery to liver .............................................................. 29 
3.5.3 Hydrodynamic hind limb perfusion ........................................................ 29 
3.5.4 Electroporation of skeletal muscle .......................................................... 30 
3.6 RNA analysis ....................................................................................................... 30 
3.6.1 Northern blot ........................................................................................... 30 
3.6.2 Reverse transcription polymerase chain reaction ................................... 31 
3.6.3 Quantitative RT-PCR .............................................................................. 31 
3.7 Protein detection .................................................................................................. 32 
3.7.1 ELISA ...................................................................................................... 32 
3.7.2 Immunoprecipitation and western blotting ............................................. 32 
3.7.3 Luciferase assay ...................................................................................... 33 
3.7.4 Histology ................................................................................................. 33 
4 Results and discussion ................................................................................................... 35 
4.1 Production of the MC vector ............................................................................... 35 
4.2 Effects of size ...................................................................................................... 36 
4.2.1 Characterization of small MC constructs ............................................... 36 
4.2.2 Construction of a small MC for vaccine purposes ................................. 38 
4.3 Protein expression from MC and plasmid vector in muscle .............................. 40 
4.4 snRNA expression from MC in muscle .............................................................. 42 
5 Conclusion and future perspectives .............................................................................. 44 
5.1 Delivery methods ................................................................................................ 45 
5.2 DNA Vaccination ................................................................................................ 47 
5.3 Ex vivo therapies .................................................................................................. 47 
5.4 Summary .............................................................................................................. 48 
6 Acknowledgements ....................................................................................................... 49 
7 References ..................................................................................................................... 51 
 
  
  
LIST OF ABBREVIATIONS 
aa Amino acid 
AFM Atomic force microscopy 
AON Antisense oligonucleotides 
AAV Adeno-associated virus 
bp 
CMV 
Base pairs 
Cytomegalovirus 
DMD Duchenne muscular dystrophy 
DNA Deoxyribonucleic acid 
E. coli Escherichia coli 
ELISA Enzyme-linked immunosorbent assay 
GFP Green fluorescent protein 
hVEGF Human vascular endothelial growth factor 
iPS cells Induced pluripotent stem cells 
kbp Kilobasepairs  
MC Minicircle 
miMC Micro-minicircle 
miRNA Micro-RNA 
mRNA Messenger RNA 
pDNA Plasmid DNA 
pre-mRNA Premessenger RNA 
qPCR Quantitative polymerase chain reaction 
q-RT-PCR Quantitative reverse trancriptase polymerase chain reacton 
RNA Ribonucleic acid 
RT-PCR 
shRNA 
Reverse transcription polymerase chain reaction 
Short hairpin RNA 
snRNA Small nuclear RNA 
TA Tibialis anterior 
TLR9 Toll-like receptor 9 
  7 
1 INTRODUCTION 
1.1 GENE THERAPY - A BRIEF OVERVIEW 
Gene therapy aims to change the behaviour of a cell by introduction of genetic material. This 
can be to replace a malfunctioning copy of a gene, as in clinical trials for treatment of X-
linked severe combined immunodeficiency, or introducing a new gene into the body to help 
fight a disease, as has been done in clinical trials for e.g. leukaemia and lymphoma where 
immune cells has been modified to destroy cancer. Gene therapy has been used in 2142 
clinical trials, with cancer diseases being the most common target.
1
 There are to date two 
commercially available approved gene therapy drugs: Gendicine containing a tumor 
suppressor gene for treatment of head and neck squamous cell carcinoma was approved in 
China in 2003, and Glybera targeting a lipoprotein lipase deficiency was approved in Europe 
in 2012. 
In order to alter the behaviour, the genetic material must be transported into the cell and reach 
the nucleus. There are two main ways to achieve this.  
1.1.1 Viral vectors 
Viruses have evolved specifically to deliver their genome to a target cell; this is how a virus 
propagates. By changing the sequence of the genetic material transported by the virus, and 
altering the virus to prevent it from being replication competent, this trait can be harnessed 
for gene therapy. Viral vectors are very efficient at delivering their cargo and are therefore 
used in nearly 70% of gene therapy clinical trials; see Table 1 for the more frequently used 
vectors.  
However, there are safety issues using viral vectors. As they originate from human 
pathogens, they can elicit an immune response. Either because the patient has already 
encountered a native strain of the virus and thus carries antibodies to the vector or because 
Commonly used viral vectors1 # clinical trials  % of clinical trials 
Adeno-associated virus (AAV) 127 5.9 
Adenovirus 471 22 
Herpes simplex virus 68 3.2 
Lentivirus 101 4.7 
Poxvirus 68 3.2 
Retrovirus 412 19.2 
Vaccinia virus 119 5.6 
Table 1. Viral vectors commonly used in clinical trials.  
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repeated treatments are needed to sustain the expression of the therapeutic gene. This is the 
case for adenovirus and AAV derived vectors, where the transgene exists as an episome in 
the cell and will be diluted with cell division, although the wild type virus can integrate in 
chromosome 19.  
Other viruses, such as retroviruses, integrate their genome into the genome of the target cell, 
and these can be engineered to do the same with a therapeutic sequence. This enables a 
constant expression in the cell and all daughter cells without the need for re-administration of 
the vector. However, the integration event can cause mutations which can have adverse 
effects. In the treatment of X-linked severe combined immune deficiency using a retroviral 
vector, the integration caused oncogenes to be activated and five of the in total 20 patients in 
the clinical trials suffered from leukaemia.
2-4
  
Another limitation for viral vectors is the size; there is a physical limit to the amount of 
genetic material that can be transported in the viral capside.  
1.1.2 Nonviral vectors 
Nonviral vectors commonly consist of naked double-stranded DNA, often as a plasmid which 
is a circular, supercoiled DNA construct produced from bacteria. The therapeutic part of a 
plasmid vector consists of an expression cassette containing a coding sequence, often a 
protein expressing gene, as well as all regulatory sequences needed for the expression and 
translation. Furthermore, the plasmid contains sequences needed for propagation in the 
bacteria, such as origin of replication and selection markers, which commonly is an 
antibiotics resistance gene. These sequences make up the bacterial backbone of a plasmid 
vector.  
  9 
Plasmid construction is relatively straightforward and permits the manipulation of a variety of 
regulatory elements that has impact on gene expression. It is easy and comparatively 
inexpensive to produce large quantities, and the possible size range of a plasmid is wide. 
Plasmid vectors are considered safer than viral vectors as they do not contain proteins from 
pathogens and thus are less immunogenic. Moreover, plasmids are episomal and non-
integrating, which reduces the risk of insertional mutagenesis as compared to e.g. retroviral 
vectors. 
However, as naked DNA lacks active transport systems for delivery into the cell and transfer 
into the nucleus, a nonviral vector is far less efficient than a viral vector and the expression is 
low and transient. There are many different approaches to improve the efficiency of these 
vectors. The plasmid can be packed together with lipids and polymers, which condense the 
DNA and protect it from degradation as well as facilitates uptake through fusion with the 
lipid bi-layer of the cell membrane. Other chemical methods to increase transport over the 
cell- and nuclear membranes is to link the plasmid construct with cell penetrating peptides 
and nuclear ligand sequences respectively. Physical delivery methods uses different forces to 
enhance transport into the target cell, such as electroporation, pneumatics and high volume 
infusions.  
Another approach to create more efficient nonviral vectors is to improve the design of the 
expression cassette itself. The regulatory sequences such as promoters and enhancers can be 
optimized to achieve high expression, cell type specific expression and long-lived expression. 
 
Figure 1. A conventional plasmid carries the expression cassette containing the gene of 
interest and regulatory sequences such as promoter and polyadenylation signal (PolyA). 
Furthermore, it needs sequences for propagation in the bacteria, as the origin of 
replication (Ori) and a selection marker, commonly an antibiotics resistance gene. These 
sequences are often referred to as the bacterial backbone of the plasmid. 
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Gill et al. discuss the selection of promoters for long term expression, and the use of tissue 
specific promoters for improved specificity and safety of non-viral vectors.
5
 Other 
components that can enhance long term expression are the inclusion of splicing elements, or 
introns, that contribute to higher gene expression.
6
 Micro-RNA sequences, on the other hand, 
can be introduced to limit expression to selected target cells while silencing it in undesired 
tissues.
7
 A method to prevent loss of gene expression due to heterochromatin spread in the 
nonviral vector is the inclusion of insulators flanking the expression cassette. A special case 
is the Scaffold/Matrix Attachment Regions (S/MAR).
8
 This AT-rich sequence acts as 
insulator against heterochromatin spread and promotes binding to the transcriptional and 
translational machinery found in the nuclear matrix. This enhances episomal establishment, 
enabling a prolonged expression also in dividing cells.
9
  
Also the properties of the plasmid vector itself affect the efficiency of a nonviral vector. As 
stated above, a plasmid needs to contain certain sequences for the production in bacteria. 
These sequences are however not needed, not even beneficial, in the target cell. Studies have 
shown that the bacterial sequences present in the vector hamper the gene expression form the 
plasmid vector.
10,11
 For example, the methylation pattern of bacterial DNA and mammalian 
DNA differs, and unmetylated CG dinucleotides, CpGs, in plasmids can trigger the immune 
response through the Toll-like receptor nine (TLR9) resulting in the loss of the cells 
harbouring the plasmid. Elevated levels of inflammatory cytokines have been shown after 
intravenous injection and after delivery to the lungs of lipocomplexed unmethylated CpG 
containing DNA in vivo.
12
 These cytokines have also been shown to inhibit reporter gene 
expression from several viral promoters.
13
 Reducing the number of CpG in a construct leads 
to a prolonged gene expression in lung whereas having even one CpG dinucleotide results 
inflammation at levels that are significantly higher than for CpG-free plasmid DNA.
5,14
 There 
is however some debate as to the importance of CpGs in gene silencing.
15,16
 Possibly, CpG 
induced gene silencing is more significant when using lipoplexion as transfection method. 
One explanation could be that the delivery pathway for lipoplexes to a higher degree puts the 
construct in contact with the TLR9 receptors located in the endosomal compartments.
17
 
However, a study investigating the effect of plasmid DNA transfer on immune and tissue 
response when using electroporation indicates that even here the CpG content is of 
importance.
18
 Although electroporation in itself activated gene pathways associated with 
muscle function and an immune/inflammatory response, electroporation together with a non-
coding plasmid DNA resulted in activation of a larger number genes involved in immune 
response. When using a CpG-free construct, the duration of the inflammatory response was 
shorter.   
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If the plasmid vector is delivered naked, other aspects could be more important. It has been 
shown that silencing of the vector can be caused by heterochromatin formation in the inactive 
bacterial sequences of a plasmid, and the heterochromatin then spreads into the promoter and 
transgene and thus hinders the expression.
19
 The vector is still present in the cell, but the gene 
is no longer active. Thus, even if the vector has been delivered to the nucleus and the 
expression cassette has been optimized, the expression often diminishes with time. These 
reasons for plasmid silencing leads us to the minicircle as an alternative to traditional plasmid 
based vectors.  
1.2 MINICIRCLE VECTORS 
 As discussed in the previous chapter, the sequences needed for propagation of a plasmid 
vector in the producer bacteria can be hampering or even harmful in the target cell. Removal 
of the bacterial backbone of the plasmid reduces the CpG-content as well as the risk of 
heterochromatin spread from inactive sequences. It also results in a smaller construct, which 
should improve the shuttling into and within the cell, and also enables a higher dose of active 
DNA.  
The minicircle (MC) is the most common vector of this type. It was first developed over 20 
years ago and although it has been used in many different areas, which will be discussed 
below, it has yet to reach the clinic. Possibly, the cumbersome production methods for the 
earlier systems have contributed to this, but also the newer and more efficient systems has so 
far only been used in vitro and in animal trials. Investigations of the possibilities and 
limitations of the systems to further develop the use of the vector are of great relevance.  
The MC is produced using a parental plasmid where the expression cassette is flanked by 
specific recombination sites. Production occurs in the bacteria; after amplification, 
recombination is induced and the parental plasmid forms two constructs: A miniplasmid 
containing the bacterial sequences and an MC containing the expression cassette with gene of 
interest and regulatory sequences.  
 12 
 
1.2.1 Systems 
Several minicircle producing systems have been published. The first publication, from 1997, 
is based on the lambda phage integrase for recombination of the parental plasmid.
20
 A later 
system is developed by Bigger et al. and utilizes a Cre recombinase expression system with 
LoxP sites flanking the expression cassette.
21
 However, the loxP-sites are still active after 
recombination and the minicircle can be lost by the cassette recombining back into the 
parental plasmid again and the sites had to be mutated to ensure unidirectionality. Mayrhofer 
et al. have published a system based on the ParA resolvase, and adding the bacterial lactose 
operator sites in the MC construct they can use affinity chromatography to purify the vector.
22
 
In all these systems, the parental plasmid and the miniplasmid remain in the bacteria after 
recombination, and since they contain the origin of replication it is possible that they will 
continue to amplify in the bacteria, diluting the minicircle.  
The system used in this thesis was developed by Chen et al. where the Steptomyces template 
integrase ΦC3 is used for recombination and the expression cassette is flanked by the attB 
and attP recombination sites.
10,23
 The resulting attR and attL sites in the minicircle and 
miniplasmid respectively cannot recombine again to reform the parental plasmid. The 
problem with separating the MC from the undesired products – the miniplasmid and any 
unrecombined parental plasmid – is resolved by introducing a rare restriction enzyme 
Figure 2. A schematic minicircle production system. Induction of recombination of the 
parental plasmid at the sites flanking the expression cassette results in the MC and a separate 
construct containing the bacterial backbone. rec1, rec2: Recombination sites; expr cassette: 
Expression cassette; Ori: origin of replication; rec12, rec21: post-recombination site-hybrides. 
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recognition site in the plasmid backbone outside the recombination sites, as well as providing 
the gene for the restriction enzyme. In the initial studies in this thesis, we used the earlier 
version of this system where the genes for the integrase and the restriction enzyme are 
encoded by the parental plasmid. Both genes were placed under the control of an arabinose 
inducible promoter. This approach resulted in a huge parental plasmid, but the upside is that 
any recombination competent Escherichia coli (E. coli) production strain can be used. 
However, most bacteria have an all-or-none arabinose import, where the level of arabinose 
inside the bacteria needs to reach a threshold level before active import is induced.
24
 This 
results in a population of bacteria which never reaches this threshold, where neither 
recombination nor digestion is induced, creating a contamination of undesired plasmids in the 
final product. The parental plasmid and the miniplasmid contain the origin of replication, so 
any copies that escape degradation can continue to replicate. 
The ΦC31-system was later refined by moving the genes from the parental plasmid to the 
bacterial genome of a bacteria strain with a constitutively active arabinose transport.
25
 This 
results in a smaller and more stable parental plasmid and purer minicircle fraction. We have 
utilized this system in our later studies.  
1.2.2 Characteristics 
The MC is, physically, much alike a normal plasmid vector in that it consists of a circular 
double-stranded DNA molecule, which is supercoiled. Both the circularity and the 
supercoiling are of interest, as is of course the fact that the MC is a smaller vector than a 
conventional plasmid.  
1.2.2.1 Size 
An MC vector containing a protein expressing gene cassette will most often encompass a few 
thousand base pairs (bp), whereas a conventional plasmid carrying the same cassette will 
often have an additional three to four thousand bp of bacterial backbone sequences. These 
size ranges are interesting in the light of studies of cytoplasmic transport, where it has been 
shown that mobility decreases with increasing size, and the pDNA fragments became 
completely immobile at the size of 2 000 bp or more.
26
  
The size of the MC vector is entirely dependent on the size of the expression cassette. A 
cassette for a short peptide would result in a rather small vector. However, the cell rarely 
expresses active short peptides such as hormones as a single peptide, but produces them as 
cleavage products from larger polypeptides. This could be to overcome structural constraints 
on the ribosome caused by the short distance between the initiation and termination codons.
27
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Despite this, there are a few publications indicating that also small peptides could be directly 
transcribed. Matza-Porges et al. have previously shown that it is possible to express a 
functional peptide as short as 15 amino acids (aa) from a Cytomegalovirus (CMV) 
promoter.
28
 Thus, it would be possible to create small MC vectors encoding short peptides.  
Cassettes encoding a short regulatory RNA, such as small nuclear RNAs (snRNA), permits 
even smaller vectors, of only a few hundred bp. In paper II, we introduce the term 
microminicircle (miMC) for a minicircle vector encoding an U7 snRNA and thereby being 
only 650 bp.
29
 When studying miMCs with different insert sizes, we observed that the 
minicircle system produced concatameric variants when the insert between the recombination 
sites was small. Regarding full length plasmid construct, i.e. still containing the bacterial 
backbone sequences, studies show that it is feasible to produce dimeric plasmids. At higher 
numbers, multimers of the plasmid construct became instable.
30
 A higher expression per 
cassette copy has been reported from a dimeric plasmid construct, but the transfection 
efficiency was lower.
31
 The multimeric MC occurs naturally in the production and would thus 
not suffer from instability in the same way as a plasmid constructed to be concatameric. 
Furthermore, a multimeric MC or miMC is a smaller construct than a multimeric plasmid and 
could thus be more efficiently transfected.  
It has been shown that the efficiency of electroporation correlates with the size of the plasmid 
DNA construct,
32
 and that there is a benefit of lower size also for lipofection in vitro
33
 and in 
vivo.
34
 Kreiss et al. discuss that the size of the pDNA may affect either the mechanism of 
DNA release from lipoplexes or for the intracellullar migration of DNA through the 
cytoplasm into the nucleus, or both.
33
 McLenachan et al. study delivery of plasmid DNA 
ranging from five to 200 kilobasepairs (kbp) to mouse embryonic stem cells and report a size 
dependant increase of nuclear delivery when using smaller constructs.
35
  
Fogg et al. study recombination of MC ranging from 250 to 1 000 bp.
36
 At the smaller sizes, 
they also report that the MC tended to form concatameric constructs rather than a monomer. 
They propose this is due to intermolecular rather than intramolecular recombination events. 
Forcing a short DNA fragment into a supercoiled construct is energetically unfavourable. 
Their observation, of a clear inverse relationship between sequence length and efficiency of 
intramolecular recombination, is in accordance with our observations in paper II. Thus, size 
has effect on the supercoiling of the MC. In the next section, I will discuss why this is of 
interest.  
  15 
1.2.2.2 Supercoil  
Any plasmid preparation will contain pDNA with different topologies: Supercoiled material, 
open circular and linear. A supercoiled plasmid becomes open circular when the 
phosphodiester bond between bases is cut in one of the strands, and there is a release of 
torsion. The plasmid is linearized when both strands are cut near or at the same base pair. The 
amount of supercoiled material is a measure of the plasmid vector quality and regulatory 
authorities require the plasmid preparation intended for vaccination or gene therapy to 
contain a high percentage of supercoiled material. In their ‘Considerations for Plasmid DNA 
Vaccines for Infectious Disease Indications’, the FDA recommends a minimum specification 
for supercoiled plasmid content of  >80%, whereas the Swedish Medical Products Agency 
only accepts a higher level of  >85% and normal industry expectation for supercoiled plasmid 
levels are  >90 or >95%.
37
  There are different rationales behind this quality requirement, 
regarding efficiency of the vector as well as pure safety concerns.   
In the paper where Chen et al. describe their initial study on the MC, the MC is also 
compared to a linear cassette excised by restriction enzymes.
10
 They measure protein 
expression after liver transfection, and it is evident that even though a linear expression 
cassette devoid of bacterial sequences results in over twenty fold higher expression than a 
normal plasmid vector, the protein production from the MC was over tenfold higher than 
from the linear cassette. Cheng et al. delivered plasmid constructs with different topologies 
using a cationic polymer and observed that supercoiled plasmids yielded higher transfection 
efficiencies than its open circular or linearized form.
38
 Remaut et al. studied this further using 
a plasmid encoding GFP, and compared nuclear and cytoplasmic injections of naked DNA as 
well as lipopfecion.
39
 From their data, it is evident that supercoiling enhances lipofection. The 
microinjection experiments point towards this being due to an enhanced transport of 
supercoiled DNA into the nucleus, as nuclear injection of pDNA resulted in the same levels 
of expression independent of the pDNA topology whereas supercoiled plasmids gave a 
higher expression after cytoplasmic injection, both in non-dividing and dividing cells. Other 
studies have also found a more efficient transfection using supercoiled plasmids over open 
circular or linearized, and attributes this to more efficient transcription.
40
 This is in 
accordance with studies showing that the degree of supercoil affects transcription efficiency 
as polymerase I prefers to initiate on negatively supercoiled templates.
41,42
 Also the binding 
of transcription factors seems to be affected, as supercoiling promotes formation of a 
preinitiation complex
43
. Supercoil can affect the accessibility of promoters and genes, as 
negative supercoil enhances formation of transcriptionally active chromatin in vitro.
44
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Apart from the benefits of increased transcription, supercoiling is also a question of safety. 
Among the risks that WHO
45
, FDA
46
 and EMA
47
 list for the use of DNA vaccines is the 
hazard of integration into the recipient’s chromosomal DNA with the resulting risk of 
insertional mutagenesis or spreading of antibiotics resistance genes. The probability of 
chromosomal integration increases if the introduced pDNA has been linearized.
48
 
As discussed in the previous section, a miMC can be very small, and the coiling could be 
affected by the short length of the DNA. The persistence length of DNA, i.e. the maximum 
length were the direction of one end is affected by the direction of the other end, is 50 nm or 
150 bp. Bending and loops at lengths below this is associated with large energy costs, and 
indeed Bates et al. report a lower limit for supercoiling at around 170 bp.
49
 They also discuss 
that the free energy for supercoiling is greater for circular DNA of less than 1 000 bp than for 
those larger than 2 000 bp. The free energy of supercoiling is length dependant at sizes below 
2 000 bp. The previously mentioned Fogg et al. study also investigates coiling of an MC 
construct of 339 bp, characterizes different topoisomers, and calculates how the strain on the 
DNA induced by coiling is partitioned into the DNA circle.
36
 However, they do not correlate 
their findings to any functional assays of the MC as a gene delivery vector. In paper II, we 
study miMCs of different sizes ranging from 650 to 1 900 bp. We study the coiling by atomic 
force microscopy, and connect these results to studies of transfection and expression 
efficiency, as well as other properties as the robustness of the vector, i.e the ability of the 
construct to withstand shearing forces.   
1.2.2.3 Robustness 
The degree of resistance to shearing forces of supercoiled MC has been investigated for a 
number of different construct sizes.
29,50
 Cantanese et al. have shown that constructs below 
1 200 bp were more resistant to the shearing forces associated with both nebulization and 
sonication whereas plasmids of conventional lengths were degraded. Nebulization to create 
an aerosol is routinely used to deliver drugs for the treatment of lung diseases. For plasmid 
delivery using nebulised aerosols, shearing of the DNA must be overcome and using MC 
vectors can be one step. Pneumatics is a promising needle-free method for drug delivery, 
especially for vaccination,
51-53
 although it is also associated with the shearing of DNA.
51
  It 
has been shown that pneumatic delivery results in 10-20% shearing for plasmids.
54
 Walther et 
al. have done a careful analysis of plasmid forms,
55
 but after ejection only, not through any 
tissue, whereas in paper II, we analyze the integrity of a conventional plasmid and miMCs of 
different sizes after the DNA has been pneumatically ejected through mouse skin. An 
interesting observation from the Catanese et al. report is that shearing causes predominantly 
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double-stranded breaks rather than nicking. This taken together with the above mentioned 
observation that linearization of DNA increase the risk of insertion into the genome makes 
the MC a safer vector than a full length plasmid when delivery methods associated with 
shearing are being used.  
The smaller vector shows increased ability to withstand not only to mechanical stress. Zhao et 
al. have studied the fate of a miMC in serum, and compare it to longer plasmid constructs.
56
  
They report that the miMC is stable in serum more than ten times longer than a conventional 
plasmid. Survival in serum could be important for in vivo delivery efficiency. Schüttrumpf et 
al. reports that loss of vector is the main reason for diminishing gene expression after 
hydrodynamic delivery to liver,
57
 so a vector with an increased stability would result in a 
more persistent transgenic effect. Schüttrumpf et al. consequently report that the expression 
loss over time was less when using the MC vector.  
1.2.3 The MC vector for substitution treatment in muscle 
In muscle, as in any target organ, most gene therapy constructs encode a protein that should 
either replace a nonfunctional gene or have an effect that ameliorates disease symptoms.  
In paper I, we compare expression of the human vascular endothelial growth factor (hVEGF) 
in skeletal and heart muscle from an MC vector to the expression from a plasmid previously 
used in clinical trials.
58
 Chang et al. have also studied the expression of hVEGF from a 
minicircle vector and compared it to a conventional plasmid. However, in vivo they only 
study skeletal muscle and compare delivery of the same weight amount of MC and plasmid 
two days after injection.
59
 Naturally, they see a higher expression from the MC, a fold 
increase that fairly well corresponds to the increased dose of therapeutic DNA.  
In an interesting combination of gene and cell therapy, Ong et al. use an MC vector to 
express a transcription factor in endothelial cells in the heart, and thus promote a preferable 
milieu for transplanted cardiac progenitor cells in vivo.
60
 The same group earlier assayed the 
MC alone, and observed expression for up to 12 weeks and improvement of ventricular 
function as well as enhanced neoangiongenesis in a mouse model of myocardial infarction.
61
  
1.2.4 The miMC for snRNA expressing cassettes in muscle 
For some muscular diseases, such as Duchenne Muscular Dystrophy (DMD), the coding 
sequence of the disease-associated gene is very large. Even though a plasmid vector can carry 
far longer sequences than a viral vector, constructs of several hundred kbp can still be 
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problematic. The human dystrophin gene covers 2.5 megabases and the resulting messenger 
RNA (mRNA) is 14 kbp.   
An alternative to replacing an entire gene is using much smaller cassettes encoding snRNAs 
aimed to alter the target gene function on an mRNA level. This can be achieved by inducing 
mRNA decay and thereby affecting protein levels, or by affecting the splicing pattern and 
thus giving rise to different spliceoforms of the protein. 
1.2.4.1 Downregulation 
Micro-RNAs (miRs) are small, noncoding RNAs of 20 to 22 nucleotides involved in gene 
regulation through translational inhibition and mRNA decay. A miMC construct encoding a 
precursor-miR involved in upregulation of angiogenic factors and cell survival was shown to 
improve heart function in a mouse model of ischemic heart disease.
62
  
Another method for downregulating protein levels is to utilize a short hairpin RNA (shRNA). 
Like miRs, shRNA can induce mRNA degradation and thus reduces protein production. The 
miMC vector has been used for delivery of shRNA producing expression cassettes. Huang et 
al. designed a dual shRNA expressing MC targeting two genes involved in the degradation of 
a transcription factor which in turn regulates hundreds of genes and protects the myocardium 
from ischemic injury.
63
 Injection of this vector into the myocardium leads to an enhanced 
stem cell mobilization and increased myocardial angiogenesis as well as improved cardiac 
function for eight weeks in a mouse model of myocardic infarction. The same group later 
used a similar strategy to improve post-ischemic neovascularization in hind limb ischemia in 
mouse.
64
 
1.2.4.2 Splice-switching 
Splice-switching aims to alter the splicing of the pre-messenger RNA (pre-mRNA). It can be 
used to induce inclusion of an intron which is otherwise skipped, as for the case of Spinal 
muscular atrophy, or to skip an intron carrying a disruptive mutation, or to rescue a frame 
shift caused by mutations, as is a possible treatment strategy for DMD. 
Splice-switching can be induced by antisense oliogonucleotides (AON) binding to the pre-
mRNA and interfering with splice sites or regulatory elements. AON therapies have been 
successful in vitro and in vivo, e.g. in animal models for DMD and spinal muscular atrophy, 
but as the effect of AONs is inherently transient, repeated treatments are needed to achieve 
sustained splice-switching.
65,66
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An alternative is to use a vector encoding the antisense sequence in the form of an snRNA. 
This enables long term expression of the splice correcting sequence. It has been shown that a 
modified version of the U7snRNA, normally involved in histone pre-mRNA 3’ end 
processing, can be used as a tool for splicing modulation.
67
 Also the U1 snRNA splicing 
factor can be modified to carry an antisense sequence targeting it to a different site. The U1 
snRNA normally base-pairs with the 5’ splice site and is important for splice site recognition. 
The single-stranded 5’ end of the U1 snRNA can be altered to carry antisense sequences to 
target it to other sequences. As it is produced from a strong and constitutive polymerase II-
dependent promoter, which works in combination with a specific termination sequence, it is 
suitable as a transgenic gene therapy cassette. To the best of my knowledge, we are the first 
to investigate the miMC as a vector for splice correction, see paper II and paper III. 
1.2.5 Other applications 
The vector is only the means to deliver a therapeutic agent, encoded by the DNA, to the target 
cell. There are many different target organs and innumerable variants for what the vector 
should encode. In the previous chapter, we have focused on muscle. In this chapter, we will 
look into some other approaches where the minicircle has been used as the delivery vector.  
1.2.5.1 Therapeutic gene expression 
 MCs expressing VEGF has not only been used for treatment in muscle, as discussed earlier, 
but also as a therapy for skin wounds in diabetic mice. Proliferating cells were transfected by 
subcutaneous delivery of MC-VEGF vectors through sonoporation,
68
 ultrasound microbubble 
destruction
69
, or formulation with a cationic dendrimer
70
. An increased blood flow and an 
enhanced wound healing were seen in all studies, and for delivery with the dendrimer an 
increased expression of VEGF was also reported.  
To make the body produce its own protein-based drugs is an appealing thought. Yi et al. have 
assayed this possibility using an MC with the nucleotide sequence of etanercept and 
tocilizumab, two protein-based drugs for rheumatoid arthritis.
71
 They report that these self-
produced drugs were functionally active after intravenous injections of the MC in an arthritic 
mice model. Another study evaluates the MC in a diabetic animal model; Alam et al. use an 
MC construct for glucose-regulated expression of insulin delivered to the liver in diabetic 
rats.
72
 They report normalized weight gain and that the treatment restores various diabetes-
associated markers of metabolic dysregulation. The MC has also been used by Park et al. to 
treat insulin resistance in obese mice by delivering the gene for adiponectin.
73
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The MC has been delivered orally, formulated as chitosan nanoparticles, to induce the 
expression of a modified factor IX in the small intestine in haemophilia B mice.
74
 Transient 
local transgene expression, clinically relevant levels of factor IX activity and partial 
phenotype correction were achieved by oral gene therapy without evidence of adverse 
immunological responses upon repeated administration. 
Hyun et al. have used the MC vector to promote stem cell survival through expression of Bcl-
2, a prosurvival protein that regulates the mitochondrial pathway of apoptosis. When treating 
stem cells with the MC, and then delivering the transfected cells to a wound, the prosurvival 
protein was overexpressed and bone formation was enhanced.
75
 There is also a study showing 
the suitability of the MC for transfecting stem cells and thus transgenically modify them 
while retaining their ability to later differentiate, suggesting that the MC might be a suitable 
vector for stem cell therapies when a transient expression is enough to stimulate regeneration 
of a tissue.
76
  
A field where the MC vector has been used in a number of studies is cancer research. 
Tumours have an enhanced permeability and retention, which allows both entry and 
sequestering of macromolecules, such as lipids, inside the tumour. Chang et al. exploited this 
property to deliver a lipoplexed MC vector to Hepatitis B Virus induced hepatocellular 
carcinoma in mice.
77
 The MC encoded a metastasis-suppressing androgen receptor, and the 
transgenic protein could be detected for up to 60 days. Wu et al. study expression of tumour 
necrosis factor alpha from MC vectors in vitro and in vivo into xenographts of 
nasopharyngeal carcinoma in mice, and show good expression in vitro and reduction of 
xenographted tumour’s growth and prolonged survival in vivo, although the MC only 
outperforms the large parental plasmid in vivo when using the same weight dose.
78
 They 
show expression in tumours for 21 days after treatment from MC, albeit declining over time, 
whereas the expression from the large parental plasmid was all but lost after seven days. The 
same group later constructed an MC encoding endostatin, an angiogenesis inhibitor, and 
evaluated it in the same xenograph model of nasopharyngeal carcinoma.
79
 They report 
reduced tumour growth for the full 20 days of the experiment as well as reduced 
vascularisation of the tumour after intratumoural injections. In an interesting cancer therapy 
study, Gaspar et al. use micelle nanocarriers to co-deliver an MC encoding the tumour 
necrosis factor alpha related apoptosis-inducing ligand and a chemotherapeutic drug, 
doxorubicin.
80
 They see good uptake in vitro and an anti-tumoural effect in mice at relatively 
low concentrations. In a cancer-related study, the MC has been used to confer in vivo ionizing 
irradiation protection by expression of manganese superoxide dismutase, a radical oxygen 
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species neutralizer.
81
 For this therapeutic approach, a transient expression is not a drawback 
as the overexpression is only needed during exposure to radiation, but high expression levels 
are needed. Therefore the MC vector was appealing. Intra-oesophageal administration or 
systemic delivery through intravenous injection of MC-lipoplexes both resulted in a greatly 
improved survival rate of the mice.  
miMCs encoding shRNAs have not only been used in muscle, but also as expression vectors 
for inhibitory agents preventing viral replication. In a study by Yang et al. two viruses that 
are major causative agents of hand, foot and mouth disease were targeted. Expression of the 
shRNAs from the miMC vector blocked the replication and gene expression of these viruses 
in vitro and in a virus-infected mouse model, with an alleviation of symptoms in the infected 
mice.
82
 In this study, Yang et al. designed a quite neat system for expression of two shRNAs 
from the same coding sequences, by flanking the sequence with two different promoters in 
different directions, as an snRNA is symmetric in sense and antisense.  
1.2.5.2 DNA vaccine 
A special case of a protein expressing vectors is a plasmid designed for DNA vaccination 
using plasmid based vectors. Among the advantages of using plasmids are the ease of both 
development and production as compared with conventional vaccine manufacturing. 
Moreover, DNA vaccines are known to be very stable at room temperature, which is of 
significance for both transport and storage.
83
 Since the antigen is expressed from pDNA 
within the target cell, the resulting peptide is more likely to resemble the native form, of e.g. a 
viral protein, with all the necessary post-translational modifications. 
In a report by Dietz et al., the MC shows promise as a DNA vaccine vector.
84
 The MC had a 
higher and prolonged expression in vitro and in vivo in mice and an enhanced 
immunogenicity in vivo. In a challenge experiment, the MC vector conferred better protection 
and elicited a stronger antigen specific CD8+ T-cell response in a mouse model of listeriosis. 
CD8+ T-cells are an important component of the cellular immune response against any viral 
infection as they can recognize and eliminate infected cells. Thus, a strong CD8+ T-cell 
response could be of extra importance for HIV vaccination. HIV mainly targets CD4+ T-cells 
and by thus affecting the function of these cells, HIV impairs the maturation of CD8+ T-
cell.
85
 Wang et al. have used an MC expressing a HIV protein for vaccination purposes.
86
 In 
their experiments, the humoral and cellular immune response when using an MC was twice 
that of a conventional plasmid. Notably, in their study they also saw that intramuscular 
injection of an MC with in vivo electroporation induced the strongest humoral and cellular 
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immune responses as compared to intramuscular injections alone, intradermal injections with 
or without electroporation, and high volume perfusion of the liver. This correlates with an 
enhanced distribution and expression from an MC vector encoding luciferase when delivered 
with electroporation.
87
 Wang et al. also report that the improvement of expression when using 
electroporation was four time higher for an MC vector than for a conventional plasmid.  
It is worth noting that for DNA vaccine purposes, the degree of supercoiling is important, as 
lower degrees of coiling has been shown to result in less efficient immunization in vivo.
88
 
Also the higher effective dose when using MC vectors is an important feature for  vaccine 
vector because, as Cai et al. note in their expert review, the amount of DNA required per 
vaccine dose is large, and this in a limited volume of a few millilitres or less.
89
 Taken 
together, these studies and observations indicate that the MC vector is a promising tool for 
DNA vaccination.  
1.2.5.3 Minicircles for gene editing 
Gene editing aims to introduce, replace or remove a given DNA sequence by the use of 
sequence specific nucleases. Dad et al. use an MC vector in vitro to deliver the genes 
encoding the programmable nuclease, both zinc finger nucleases and transcription activator-
like effector nucleases.
90
 The higher vector copy number and increased expression from the 
MC vector results in a higher mutation frequency. Delivering the nucleases via an MC vector 
is also better tolerated, with higher cell viability as compared to a normal plasmid.  
1.2.5.4 Minicircles for induced pluripotency 
Induced pluripotent stem cells (iPS cells) are a type of stem cell that can be generated from 
adult cells by introducing a specific set of pluripotency-associated genes. In a brief 
communication, Jia et al. reports the use of MC vectors for iPS-cell formation from adult 
human adipose stem cells.
91
 They clone an MC with a single cassette of four reprogramming 
factors, OCT4, SOX2, LIN28 and NANOG, together with a GFP reporter gene. Using three 
repeated nucleofections, and selection of GFP-positive cells, they obtain colonies with 
embryonic stem cell morphologies and can show pluripotency and expression of embryonic 
germ layer genes in these cells. The efficiency was low compared to viral methods, but higher 
than when using plasmids. Furthermore, they show that the vector did not integrate into the 
genome, so the MC induced iPS cells will over time be free from foreign elements.  
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2 AIM 
This thesis aims to optimize and evaluate the MC as a nonviral vector for gene therapy, with 
special focus on delivery and expression in heart and skeletal muscle and on the effects of 
using a small expression cassette encoding an snRNA.  
The specific aims were:  
1. To thoroughly investigate the effect of size on coiling patterns and relate these results 
to studies of transfection and expression efficiency, as well as to other properties such 
as the robustness of the vector.   
2. To evaluate the use of the MC vector for therapeutic protein expression in heart and 
skeletal muscle. 
3. To evaluate the use of the miMC for splice-switching therapies, especially in skeletal 
muscle.  
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3 METHODOLOGY 
Numerous methods where used during this work. In this chapter, many of them will be 
discussed with some theoretical aspects.  
3.1 CONSTRUCTS AND MC PRODUCTION 
For paper I, the expression cassette containing a CMV promoter, the gene for hVEGF-165 
and a rabbit β-globin polyadenylation site was cloned from the phVEGF165-vector into the 
p2ΦC31 MC producing plasmid between the two recombination sites. This was the first 
generation of the ΦC3 MC producing system developed by Chen et al.10,23 In this system, the 
inducible genes for the recombinase and endonuclease are located on the parental plasmid 
and production could be performed in any recombination competent E. coli production strain. 
After over-night propagation of the transduced bacteria, addition of arabinose induces the 
pBAD-promoter controlling the Streptomyces phage ΦC31 integrase gene and the I-Sec-I 
endonuclease gene. Thus, recombination of the parental plasmid into the MC and 
miniplasmid was induced, as well as linearization of the miniplasmid by the endonuclease at 
the recognition sites located outside the recombination sites. This step took place at 32 ºC at 
increased pH to improve the efficiency of the enzymes. After five hours, the bacteria are 
harvested and the MC vector purified.  
In papers II and III, the improved system with the specialized ZYCY10P3S2T bacteria strain 
was used.
25
 The expression cassettes used was U7asLuc with antisense sequences targeting 
the mutated β-globin intron92 (paper II)  and U7asDys with a sequence targeting across the 
splicing branching point in intron 22 and the U1 binding region at the donor site in intron 23 
in mdx dystrophin pre-mRNA
93
 (paper III). The modified U7 gene, along with its natural 
promoter and 3’ elements was cloned into the pMC parental plasmid between the two 
recombination sites. After transduction of the ZYCY10P3S2T bacteria, carrying the inducible 
genes for the ΦC3 integrase and the I-Sec-I endonuclease, miMCs were produced according 
to the method published by Kay et al.
25
, a method much similar to the one described above.   
All the MCs used in the papers included in this thesis were produced in small scale 
fermentations in a shaking incubator. In an experiment to produce MCs on a larger scale, we 
utilized a pilot plant scale fermentor. A fermentor is a type of bioreactor containing and 
controlling the culture of microorganisms, in our case bacteria. The fermentor contains a 
suitable growth medium and has been inoculated with a bacteria culture to start the 
fermentation process. It controls the temperature, pH, ventilation and agitation of the culture. 
It can also be set to control the conditions of nutrients by using a fed-batch system that adds 
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buffers continuously or at set time points during the fermentation process, e.g. for induction 
of recombination by addition of arabinose. Fermentation allows for a much higher density of 
bacteria and thus a higher yield of plasmid or MC DNA. 
MC DNA was purified using commercial kits from QIAGEN (Hilden, Germany) according 
to protocol, with the modification that larger buffer volumes are needed for the lysis steps. 
After purification, quantity and quality was assayed using UV spectrophotometry at 260 nm 
and agarose gel electrophoresis. 
For analysis of multimers in paper II, it was important to have only one isomer present in the 
final product. We therefore performed an additional gel separation and purification of the 
isomer of interest. MC DNA was separated by size on an agarose gel. Care was taken to 
avoid nicking the DNA by UV light or intercalating dye: the isomer’s position in the gel was 
marked on stained edges of the gel and the corresponding band excised from the unstained 
gel. The monomer was then extracted from this gel fragment by QIAquick Gel Extraction Kit 
(QIAGEN) according to protocol and further purified by phenol:chloroform extraction. This 
is a cumbersome process and has a low yield, but was necessary for the experiments in 
paper II.  
3.2 VISUALIZATION BY ATOMIC FORCE MICROSCOPY 
Atomic Force Microscopy (AFM) is a type of scanning probe microscopy which measures 
the force between the tip of a probe and the sample, raster-scanning over a small area of the 
sample. When the tip is brought into proximity of a sample surface, forces between the tip 
and the sample lead to a deflection, which when measured, can be translated into a spatial 
map of the surface.  The resolution of the technique is high; fractions of nm.  
Advances in the methodology of AFM enable reliable imaging of DNA in various structures 
and topologies.
94
  The nucleic acid chain is mounted on the ultraflat surface of freshly cleaved 
mica. Unmodified mica has a negative surface charge; however modification of a mica 
surface with 3-aminopropyltriethoxy silane (AP-mica) leads to a reduction in surface 
potential. DNA binds to AP-mica primarily due to electrostatic interactions between the 
protonated amino groups of the AP-mica substrate and the negatively charged DNA 
backbone. The low surface charge density of AP-mica allows immobilized supercoiled DNA 
to retain its geometry. The overall geometry of supercoiled DNA is rather labile and sensitive 
to environmental conditions, such as salt. Correct salt composition in the buffers enables 
preservation of the morphology of the supercoiled DNA molecules.
95
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In paper II, we used AFM to visualize the coiling patterns of the miMC DNA and plasmids. 
A volume of 30µl DNA, diluted to 0.5 µg/µl in 50 mM NaCl, was added to the AP-mica 
surface, incubated for five minutes and then rinsed by water. When dry, the samples were 
measured in air in soft tapping mode with scan rate of 1Hz. A diamond-like carbon tip 
cantilever with a resonant frequency of 115-190 kHz was used on a NanoScope V Atomic 
Force Microscopy (Veeco®, Santa Barbara, CA) equipped with J piezoelectric scanner. 
3.3 TESTING OF ROBUSTNESS BY PNEUMATIC DELIVERY 
In paper II, we chose to evaluate the ability of plasmid constructs and MCs of different sizes 
to withstand the shearing forces induced by pneumatic delivery by ejecting the DNA through 
mouse skin using a Biojector (Bioject Medical Technologies Inc, CA, USA) and analyzed the 
integrity by gel electrophoresis.  
The Biojector is a needle free system for drug delivery by forcing liquid medication through a 
tiny orifice that is held against the skin. Pneumatics and the small diameter of the orfice 
create an ultra-fine stream of high-pressure fluid that penetrates the skin without using a 
needle. The Biojector can deliver injections to a number of depths, with intramuscular 
injections being the deepest injection type, delivering the medication into the muscle tissue. 
Most vaccines are currently delivered to the intramuscular depth. The Biojector can also 
deliver subcutaneously to the adipose layer below the skin, as well as intradermally. 
3.4 CELL LINES AND IN VITRO TRANSFECTION 
The transfection methods used in this thesis aims to transport plasmid based DNA constructs 
through the cell membrane and cytoplasm into the nucleus, where it can be transcribed.  
3.4.1 Lipofection 
Lipofection is a chemical transfection method utilizing the fact that cationic lipids can form 
complexes with DNA, condensing and shielding the negatively charged DNA. These 
lipoplexes can fuse with the cell membrane to deliver the enclosed DNA. In paper II, a 
nanoparticle tracking analyzer (NanoSight, Amesbury, UK) was used to measure the size 
distribution of particles of DNA after complexation with Lipofectamine 2000 
(ThermoScientific, MA, USA). The particles contained in the sample are visualised by the 
light they scatter when illuminated by laser light and the movement of the particles is 
correlated to the hydrodynamic radius and Brownian motion which enables calculation of 
size and concentration.  
 28 
 In paper I, FuGENE 6 (Roche, Mannheim, Germany) was used for lipofection of MC 
construct into HT-1080, a human fibrosarcoma cell line, with a reagent:DNA ratio of 3:1 as 
per protocol. Cells were seeded one day prior to transfection in an appropriate density so that 
they are 70-80% confluent at the day of transfection. Cells were processed 48 h later. 
The cells used in paper II, HeLa Luc/705 cells, are stably expressing a Luciferase gene in 
which the coding sequence is interrupted by a mutated β-globin intron.92 The cells were 
transfected using Lipofectamine 2000 (ThermoScientific) according to manufacturer’s 
protocol. Briefly, cells were seeded one day prior to transfection in an appropriate density so 
that they are 70-80% confluent at the day of transfection. DNA was complexed using 2.3 µl 
of Lipofectamine 2000 per µg of DNA in opti-MEM (ThermoScientific). Cells were 
processed 24 h after transfection. 
The mouse H2K cell line used in paper III is a myogenic cell line derived from the mdx 
transgenic mouse which carries a point mutation in exon 23 of the dystrophin gene.
96
 The 
cells were transfected using Lipofectamine 2000 according to manufacturer´s protocol. 
Briefly, 2.3 µl of Lipofectamine 2000 was used per µg of DNA. Complexes were formed in 
50 µl opti-MEM and added to cells grown in 450 µl full growth media. Cells were processed 
48 h later. 
3.4.2 Electroporation 
In paper II, the HeLa Luc/705 cells were also transfected using electroporation. 
Electroporation is a physical transfection method which enables direct delivery over the cell 
membrane and into the nucleus. In paper II, we used it for comparison of physical and 
chemical MC delivery methods. Electroporation occurs when an external electric field is 
applied to the cell and the transmembrane potential exceeds a critical threshold.
97
 This leads 
to a transient permeabilization of the plasma membrane, possibly through the creation of 
nanoscale pores, that allows DNA delivery into cells, but the mechanism is not entirely 
known.
98
 In our work, we used the 100 µl tips of Neon system (ThermoScientific) in which 
cells are treated in suspension in a pipette tip chamber where the electric field is generated.   
3.5 IN VIVO DELIVERY 
3.5.1 Intramuscular injection  
Direct injection of pDNA into muscle results in expression of the DNA in myofiber cells. 
Uptake and expression of numerous transgenes have been demonstrated in various species 
following intramuscular injections of naked DNA.
99
 The expression peaks after a few days 
  29 
and then drops to a lower but steady expression, and can be detected for a very long time in 
some cases.
100
 However, the efficiency of pDNA gene transfer into skeletal muscle is low, 
with around one percent of the cells being transfected after an intramuscular injection.
101
 
Also, expression is only seen in a very restricted area of the muscle, usually along the needle 
track. 
In both paper I and paper III intramuscular injection was chosen as it is a straightforward 
delivery method suitable for the proof of principle experiments performed in these papers. 
Material was delivered to the tibialis anterior (TA) of anesthetized mice by intramuscular 
injection of DNA in saline. In paper I, plasmid and MC was also injected into to the heart 
muscle. Anesthetized mice where tracheotomized, and through a left thoracotomy, the heart 
was exposed and injection was performed. Ten microliters of plasmid or MC solution in 
physiological salt buffer was administered. 
3.5.2 Hydrodynamic delivery to liver 
Hydrodynamic infusion is a well-documented gene transfer technique, known to give a high 
transfection efficiency of the liver in mice.
102
 By rapid injection of a relatively large volume 
of DNA solution, a controlled hydrodynamic pressure arises in the capillaries which enhance 
cell permeability and allows for entry into the hepatocytes. The discontinuous sinusoidal 
capillaries in liver are sensitive to the hydrodynamic procedure, and the high pressure is 
thought to induce membrane pores in the hepatocytes which are responsible for intracellular 
DNA transfer. When the pressure is reduced, the pores close and the material is trapped 
inside the cell.
103,104
  
In paper II, the functionality of a miMC for splice correction was tested with co-injection of a 
luciferase reporter construct and a splice correcting plasmid or miMC by hydrodynamic 
delivery to mouse liver. Mice were treated with a two ml hydrodynamic infusion through the 
tail vein while anesthetized, the volume being about 10 % of the mice body weight. This 
allowed us to assay the long term expression in vivo. 
3.5.3 Hydrodynamic hind limb perfusion 
The use of rapid injection of a large volume of pDNA solution through a peripheral blood 
vessel into a limb that is temporarily isolated from normal blood flow by a clamping induces 
a high pressure and thus increases gene delivery also in skeletal muscle cells.
105
 The high 
pressure allows macromolecules to pass through transient pores in the normally very 
impermeable endothelium of the skeletal muscle. High-pressure transvenous limb perfusion 
has even been tested in a clinical trial on dystrophic patients and found safe.
106
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In paper III, hydrodynamic hind limb perfusion was performed in an attempt to enhance 
miMC delivery to skeletal muscle. High volume perfusion of mdx mouse hind limb was 
performed under general anaesthesia and as described by Gonin et al.
107
 The mice were 
injected with miMC in one ml 0.9% saline, clamping was maintained for 10 min after 
injection. 
3.5.4 Electroporation of skeletal muscle 
Electrotransfer in vivo is based on injection of pDNA solution into the muscle, followed by 
the application of as series of electric pulses over the tissue. Electroporation has been shown 
to increase the gene transfer not only by cell permeabilization but also by a direct active 
effect on the DNA molecule, promoting DNA migration and cellular uptake. But as for in 
vitro electroporation, the exact mechanism of uptake is debated.
108
 Pre-treating the muscle 
with bovine hyaluronidase has been shown to ameliorate the cell damage associated with 
electroporation.
109
  This method is reported to result in a higher transduction than high 
pressure delivery methods, resulting in expression levels comparable to those achieved with 
viral vectors.
110
 Even though electroporation is a rather invasive method for gene delivery, 
studies have shown that it is feasible to deliver nonviral vectors in vivo using electroporation 
even to the diaphragm of rats.
111
 
In paper III, electroporation was performed to enhance the efficiency of intramuscular 
injection of miMC into skeletal muscle. Hyaluronidase treatment, injection and 
electroporation of mdx mice was performed according to protocol by Wells et al.
112
 
3.6 RNA ANALYSIS 
Gene expression and splice-switching can readily be measured by RNA analysis.  
3.6.1  Northern blot 
Northern blotting is a method to detect a specific RNA by separating a total RNA population 
according to size by gel electrophoresis, transferring the RNA to a membrane and label the 
desired RNA with a detectable antisense probe. The probe can be labelled with radioactivity 
or chemiluminescence, which allows for quantification of the signal. For northern blotting, as 
opposed to reverse transcription polymerase chain reaction (RT-PCR) discussed below, there 
is no amplification of the sequence before detection. Therefore, it can be difficult to detect 
low abundant RNA, but there is no risk for amplification errors affecting the measurements. 
Northern blots were used in paper II to detect expression of U7snRNAs from miMC in mouse 
liver samples.  
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3.6.2 Reverse transcription polymerase chain reaction 
RT-PCR utilizes the PCR method to amplify a sequence of interest, and can thus be used to 
detect lower levels of RNA. The sequence is first translated from RNA to cDNA using a 
reverse transcriptase. The cDNA can then be used as template in a PCR reaction. As any PCR 
reaction, it is sensitive to contaminations being amplified. Traditional PCR runs to end point, 
and the sample is then analyzed by gel electrophoresis. Thus, the method is semiquantitative, 
even though simultaneous amplification of an endogenous control RNA, which should not be 
affected by the treatment, allows for normalization and comparison between samples. 
Designing primers that span over several exons enables detection of splice variants of 
mRNA.  
In paper II and paper III, semiquantitative RT-PCR was used to detect splice variants of the 
reporter Luciferase mRNA and of mdx dystrophin mRNA as it enables amplification with the 
same primer pairs for both splice variants followed by easy visualization by gel 
electrophoresis.  
3.6.3 Quantitative RT-PCR  
Quantitative RT-PCR (q-RT-PCR) is the most sensitive method to detect RNA. As in normal 
RT-PCR, the RNA is first translated to cDNA using a reverse transcriptase enzyme, and the 
product is then used as template in the quantitative PCR reaction (qPCR). Using SYBRGreen 
as a fluorescent intercalator allows for quantification of the number of double-stranded 
molecules in the reaction. Using a probe that binds to a specific target and which is labelled 
with a fluorophore and a quencher that is cleaved off when the polymerase transcribes the 
target enables a more specific detection. The intensity of the fluorescence increases as the 
PCR products accumulate, until it reaches a plateau. For measurements made in the early 
exponential phase of the PCR, the fluorescence level can be correlated to the amount of 
starting material.  
q-RT-PCR was used in paper II and paper III to measure the expression levels of the 
U7snRNAs and compare different delivery methods and vector sizes. It is evident in paper II 
that the increased sensitivity of the q-RT-PCR can detect differences in U7snRNA levels 
even where the secondary effects on mRNA correction are too small to be detected with the 
semiquantitative RT-PCR. 
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3.7 PROTEIN DETECTION 
3.7.1 ELISA 
Enzyme-linked immunosorbent assay (ELISA) is a method to quantify the amount of a 
certain protein using antibodies targeting an epitope on that protein. The sample is 
immobilized on a surface and the antibody is allowed to bind to the target protein. By 
coupling the antibody to an enzyme, either directly or via a secondary antibody, and 
subsequently add a colour-changing substrate for the enzyme, it is possible to measure the 
colour change and thereby the amount of protein. A standard curve of known amounts of 
protein is used to quantify the measurements.  
In paper I, ELISA was used to straightforwardly quantify the amount of hVEGF after MC 
delivery in cell medium and tissue samples.  
3.7.2 Immunoprecipitation and western blotting 
Other antibody based method for protein capture and identification is immunoprecipitation 
and western blotting. In immunoprecipitation, the protein in question is fished out of the 
crude cell lysate using an antibody directed to a suitable epitope on that specific protein, and 
the antibody is in turned captured e.g. by protein G coated magnetic or agarose beads or using 
protein G spin columns. This allows for concentration of the protein before analysis. The 
captured protein can then be eluted and analyzed e.g. via western blotting, if possible using a 
primary antibody of another species than the one used for immunoprecipitation. As the 
protein amount has been concentrated, quantification is more difficult than when running 
western blots on crude cell lysate.  
In western blotting, much like northern blotting for RNA, the sample is first separated by size 
on a gel and then transferred to a solid membrane and probed for identification. For western 
blotting, the probe is an antibody with a suitable epitope on the protein in question. A 
measurable signal is produced using and antibody coupled to a radioactive isotope, a 
fluorophore or an enzyme for chemiluminescent detection. A common problem with western 
blotting is unspecificity of the antibodies, which leads to difficulties interpreting the results. 
Unusual or unexpected bands can also be due to protease degradation, which produces bands 
at unexpected positions. It is important that the cell lysate is prepared in the cold, and that 
appropriate protease inhibitors are used.  
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3.7.3 Luciferase assay 
Luciferase is an enzyme that converts the substrate luciferin to a light in an ATP-dependant 
reaction. The Luciferase gene is a common reporter gene, as quantification of protein 
amounts is very straightforward: Cells are lysed and after addition of the substrate, the 
emitted light can be measured by a luminometer. Luciferase can also be measured in vivo by 
injecting the substrate into a living mouse which can be imaged and the protein levels 
quantified. Since light excitation is not needed for luciferase bioluminescence, there is 
minimal disturbance by autofluorescence.  
Gaussia Luciferase was used in paper I for normalization of transfection efficiency. In paper 
II, the gene for firefly luciferase with a mutated 705 human β-globin mini-intron sequence 
inserted was used as reporter in the splice-correcting systems.
92
 Expression of the gene with 
the mutated intron results in a truncated non-functional Luciferase protein. Masking the 
mutated site with an antisense sequence, however, redirects the splicing machinery that 
concomitantly gives rise to productive splicing of the Luciferase pre-mRNA and transcription 
of a functional protein. Thus, the levels of luciferase signal indicated the levels of splice-
correction by the U7snRNA expressed from the miMC.  
3.7.4 Histology 
Histology is a method to study the morphology, architecture and composition of cells or 
tissues using microscopy. It allows visualization of the distribution and localization of 
specific cellular components. The sample is fixated either chemically or by snap freezing, 
sectioned and the thin sections are mounted on glass slides. Fixation preserves the structural 
integrity of the cells and tissue. However, chemical fixation can damage the biological 
functionality of proteins, particularly enzymes, and can denature them to a certain extent. It is 
also harmful for RNA and DNA.  
After sectioning and mounting, the sample is stained. Different staining techniques are 
available to preferentially colour components of interest in the sample. Hematoxylin and 
eosin staining colours the nuclei dark blue by hematoxylin while the cytoplasm and 
extracellular matrix are coloured in varying degrees by eosin. It is used to visualize the 
general structure and integrity of the sample. Immunohistochemistry and 
immunofluorescence uses antibodies to identify tissue components of interest by binding of a 
primary antibody to the protein of interest. In direct detection methods, the primary antibody 
is labelled, whereas in indirect methods a secondary antibody is used for detection. Indirect 
detection allows for binding of several secondary antibodies to the primary, and thus a 
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stronger signal. The detection antibody can be coupled to an enzyme, for 
immunohistochemistry, or a fluorophore, in immunofluorescence. The fluorophore can be 
imaged directly by a fluorescent microscope, but the enzyme needs addition of its substrate to 
create a detectable staining of the sample. The resolution of subcellular structures is not as 
good using enzymatic detection as with fluorescence methods but can be combined with 
electron microscopy, and the shelf life of the labelled specimen is virtually unlimited. 
Histology is used in paper III to visualize restoration of dystrophin expression in mdx mouse 
muscle tissue after delivery of miMC by electroporation. Although levels of U7snRNA 
expression and exon skipping in the mRNA are important indicators of the effect of the 
miMC, only actual restoration of dystrophin protein will have a physiological effect on the 
muscle and immunohistology allows us to visualize it in the muscle cells.  
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4 RESULTS AND DISCUSSION 
4.1 PRODUCTION OF THE MC VECTOR 
The future use of minicircles in gene therapy demands an effective production and 
purification system with high yield. To produce the quantities needed for clinical studies and 
clinical use, the system must be robust and effective.  
As we experienced an impure MC product using the first generation Chen system and their 
protocol for MC production, some effort was made to improve the system. We analysed a 
number of different bacteria strains, and found that using the O17 E. coli strain, known for its 
high protein production efficiency and kindly provided by Leif Isaksson at Stockholm 
University, resulted in improved recombination and degradation. We also tried co-fermenting 
the MC plasmid with a plasmid constitutively expressing arabinose importin, but it was 
difficult to balance copy number rate of the two plasmids in the bacteria.  
In order to produce quantities required for clinical use, the process needs to be scaled up from 
shaking incubators to fermentor scale. A pilot plant scale fermentation experiment on the first 
generation system was performed with 5 litre medium in a Novaferm (Falkenberg, Sweden) 
fermentor. The parental plasmid was grown over night, and then induced by injection of 
arabinose and continued growth for four hours. One 5 litre fermentation batch gave 65 mg 
plasmid product but it had a very high content of unrecombined and undigested plasmids, 
containing only 15% MC. This initial study of scaling up the MC production system showed 
that a high yield of plasmid can be obtained, but the dosing of arabinose and probably also 
the pH needs to be fine tuned in order to reach higher purity in the final product. Also the 
growth temperature could influence the yield of MC. Gaspar et al. evaluate different 
conditions and conclude that an elevated temperature gives a better yield.
113
 Even if this in 
our hands had little effect on a shaking incubator culture, it could be a parameter to 
investigate for larger scale fermentation.   
When Kay et al. published their improved system with the specialized ZYCY10P3S2T 
bacteria bacteria strain,
25
 we were able to use that instead. However we never tried this 
system in a fermentor. Using this system, we have seen that we can improve the yield of 
small MC vectors by adding L-arabinose at several time points during the induction phase of 
the fermentation, to mimic a fed-batch fermentation.  
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4.2 EFFECTS OF SIZE 
4.2.1 Characterization of small MC constructs 
During production of our smallest miMC construct of 650 bp in paper II, it was evident that 
multimerization was more common than for the larger constructs. This could be due to steric 
strain on the DNA, hindering the recombinase from joining the two recombination sites on 
same the parental plasmid. This strain could also affect the ability to supercoil the constructs. 
Thus, we studied coiling of MC of different sizes and plasmids via AFM. AFM allowed us to 
visualize the coiling pattern and characterize the number of turns in the constructs. However, 
the AFM images in paper II show clear supercoiling patterns. Also the smallest construct 
exhibited patterns that Fogg et al. associate with high writhe and increasingly negative 
supercoiling.
36
 The number of turns is evidently related to the size of the MC but not strictly 
correlating 1:1 as the smaller one has predominantly two to three turns, and doubling the size 
gives four and five turns, and three time larger construct shows five to six turns. Also, as the 
constructs grow larger, the topology resembles the plasmid more. Thus, the strain could be 
higher on the smallest constructs. The in vitro transfection experiments showed that the 
smallest construct has a lower expression than the two times larger construct, irrespectively 
of if the larger construct is a dimer or if it contains irrelevant DNA to simply increase the 
size. This could be due to the relatively high degree of supercoil of the smallest construct, 
which could hinder the binding of necessary protein components. It is known that the 
curvature of the DNA affects the accessibility to cis-DNA elements by inducing different 
chromatin formations and that bending of the DNA changes the affinity of promoter binding 
proteins as the energy cost of bending contributes significantly to the overall binding affinity 
of the transcription factors for different sequences.
114-116
  
For a small construct, a certain molar dose of expression cassettes corresponds to a lower 
weight amount of DNA than the same number of expression cassettes in a larger construct. 
This evidently affects transfection efficiency when using lipofection, as we showed in paper 
II. It is quite logical that a lower weight amount of DNA will result in fewer lipoplexes and 
thus reach fewer cells, albeit with a higher molar dose for each lipoplex. Our nanoparticle 
analysis data shows, as expected, that the size and number of lipoplexes are in the same range 
for the same amount of DNA, irrespectively of the content. This should be taken into 
consideration when using small constructs such as MC or especially miMC. Interestingly, Wu 
et al. see the opposite trend, and strangely enough reports the highest in vitro expression from 
the lower molar dose transfected without stuffer DNA, even in comparison to a seven times 
larger weight comparison dose.
78
 They attribute this to lower toxicity due to lower amounts of 
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lipofectamine, and one hopes that the toxicity at the higher doses did not occlude any other 
results. When using electroporation however, it is evident from the results in paper II that a 
larger dose of DNA is not beneficial. As discussed before, using MCs allows for using a 
lower amount of DNA while still delivering a high number of expression cassettes. When 
Madeira et al. use electroporation to transfect neural stem cells, they see a higher amount of 
MC in the cells as compared to a plasmid, and attribute this partly to the smaller size of the 
MC vector.
76
 The same group also reports a size effect for different plasmid constructs when 
electroporating stem cells, and discusses that this could be due to better uptake of the smaller 
construct.
117
  
When using hydrodynamic delivery to liver, as in the in vivo studies in paper II, the material 
is forcibly pushed into the cells as the organ expands causing enlargement of liver fenestrae 
and generation of transient pores in the plasma membrane of hepatocytes of the liver. This 
method is thereby not dependant on formulation or active uptake. Thus, as expected, there 
was no effect of adding stuffer DNA to keep the total amount of DNA equal. In these in vivo 
experiments, there is a higher and more sustained expression from the miMC as compared to 
the plasmid. We used co-delivery of a reporter plasmid carrying the mutated luciferase gene 
for the splice correction, and assayed two different reporter constructs. In the first experiment, 
the reporter gene expression was driven by a CMV promoter, and there was a drop in 
luciferase signal after one week. When re-administrating the reporter construct, it was evident 
that the miMC still expressed the splice-correcting snRNA, as the luciferase signal returned, 
but the expression from the splice-correcting plasmid had been lost. In a follow up 
experiment, we used a reporter construct designed for a long term expression in liver. 
Throughout this in vivo experiment, all mice treated with splice-correcting constructs had a 
higher expression than the control mice, which only received the reporter plasmid together 
with an empty plasmid. One day after infusion, mice treated with miMC had about 20% 
higher luminescent signal as compared to the mice treated with splice-correcting plasmid. 
Over time, the signal from the plasmid declined more rapidly compared to the miMC and at 
the final time point the miMC treated mice had a several hundred percent higher signal than 
the plasmid group. Even here there is a gradual drop in luciferase signal over time also for the 
miMC treated mice, but it matches the curve from the control mice. 
It is possible that an increased robustness of the miMC contributes to the higher expression 
and effect that we and others have seen repeatedly using the hydrodynamic delivery 
method.
10,15,57,118
 In paper II, we demonstrate a higher robustness of our small miMC 
constructs as compared to the larger and to a conventional plasmid. The fate of the miMC or 
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pDNA after delivery through mouse skin using pneumatics was assayed. As discussed earlier, 
pneumatics is known to cause shearing of DNA. The miMC, however, seems to be able to 
withstand these shearing forces to a much greater extent than the plasmid. What is perhaps 
most noteworthy is that the plasmid DNA is partially destroyed and does no longer meet the 
FDA requirements of an 80% supercoiled fraction. The MC construct fared much better, with 
the nicked fraction being ten times lower than for the full length plasmid construct. This 
shearing of the plasmid may not only increase the risk of insertional mutagenesis but also 
results in a lower effective dose, since linearized and open circular topologies have been 
shown to have lower transfection efficiencies and expression.
88,119
 Our results are 
corroborated by the experiments on serum stability and ability to withstand shearing forces 
associated with sonication and nebulization discussed earlier.  
4.2.2 Construction of a small MC for vaccine purposes 
The increased robustness has implications for DNA vaccination, since pneumatics is a 
method used for delivery of DNA vaccine. As it could be beneficial to use a small expression 
cassette, short immunogenic peptides are of interest. A candidate short peptide is the T20 
peptide, also known as enfuvirtide. It is the first HIV-1 fusion inhibitor peptide-based drug to 
be approved for treatment of AIDS patients, under the brand name Fuzeon.
120,121
 T20 consists 
of 36 aa mimicking the C-helix sequence of the HIV-1 envelope transmembrane domain 
gp41. T20 blocks the early step in the virus life cycle prior to reverse transcription and can 
prevent de novo infection and cell-to-cell virus transmission. Although it has been previously 
shown that gp41 antibodies do not impair T20 antiviral effect in the treatment of HIV, little is 
known about the immunoprotective properties of T20 itself.
122
 The T20 peptide can be 
recognized as an HIV antigen since it contains a broadly reactive epitope, the so called 2F5 
epitope.
123
 This immunoreactive activity of the T20 peptide would results from the fact that 
the peptide mimics residues 643-678 of the HIV-1 glycoprotein gp41. Thus, any antibodies or 
CTL reactivity formed against the T20 peptide will also find epitopes of this critical region of 
the HIV-1 transmembrane protein.  Natural antibody responses to gp41 and the entire gp120 
occur soon after HIV-infection, and can result in neutralizing antibodies.  
In an ongoing study by Hinkula et al., the T20 peptide has been evaluated as a part of an HIV 
protein/DNA vaccine. Figure 3 shows that administering the T20 peptide together with the 
HIV-1 DNA vaccine constructs enhances anti-Env immunogenicity.  
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Therefore, we have cloned the T20 coding sequence and an expression cassette previously 
used in HIV inhibition studies
124
 into pMC-vector for MC-production. The construct 
containing the T20 coding sequence was donated by Drs K. Cheng and D. Goldenberg, 
Immunomedics, see also Chang et al.
125
 The resulting MC was 1.1 kbp, i.e. less than one 
third of a corresponding conventional plasmid. 
The MC was transfected into HeLa, Hek and U2OS cells using Lipofectamine 2000 
according to manufacturer’s protocol and 24 µg to a 10 cm plate. Figure 4 clearly shows the 
expression of ssT20 in vitro 48 hours after transfection, both in an immunoprecipitated 
sample and in crude cell lysate. The prominent bands of larger molecular weight are the 
heavy and light chain of the antibody used in immunoprecipitation. As the same antibody was 
used for the western blot, also these were detected by the secondary antibody. Evidently, it 
thus is feasible to produce immunogenic peptides as small as 36 aa transgenically in human 
cells. T20 has previously been expressed as a multimeric fusion protein, which was shown to 
 
Figure 3. A comparison of intranasal (i.n.a) deposition of medium, T20 peptide alone, 
DNA vaccine plasmid gp160 alone or T20 mixed with plasmid gp160. T20 peptide 
mixed with the plasmid appears to enhance both serum IgG titres of binding to gp160 as 
well as neutralizing antibodies (NT) to HIV-1 subtype B. Hinkula et al, manuscript. 
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have an antiviral effect in vitro.
126
 Dervillez et al. also expressed the C46 peptide, a T20 
derived peptide, alone and showed expression but no secretion of the peptide.  However, they 
did not study the immunogenicity of their peptide construct. For immunostimulation, 
secretion is not crucial, since the transfected cells will present the antigen on MHC 
molecules. T20 can thereby be recognized as foreign and trigger an immune response. Here, 
we show that the MC vector can express the monomeric T20 peptide in human cell lines, and 
the protein was detectable by western blotting using the neutralizing human antibody 2F5. 
Further studies will show the immunogenic properties of the T20 peptide expressed from an 
MC vector in vivo. 
 
4.3 PROTEIN EXPRESSION FROM MC AND PLASMID VECTOR IN MUSCLE  
Treatment of ischemic tissue with growth factors such as VEGF had shown promising results 
in animal experiments but clinical trials were disappointing.
127
 This was in part attributed to 
the short half-life of the growth factor in vivo. Transgenic expression in the tissue is a 
possible and interesting solution to this problem. However, problems preventing successful 
clinical application of gene therapy for cardiac diseases can primarily be related to inefficient 
gene transfer, host immune responses, and the lack of sustainable therapeutic transgene 
expression. As the MC vector addresses two of these problems, we designed a study in paper 
I where we compare the expression of hVEGF protein from an MC vector to plasmid 
constructs. In this study, three different full-length plasmid constructs were used in parallel to 
 
Figure 4. Expression of T20 peptide from MC vector in vitro. A western blot on 
immunoprecipitated (IP) peptide  and cell lysate from HeLa cells transfected with 
MC or untransfected (control).  
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the MC vector. A plasmid vector, which had been previously used in clinical studies, 
phVEGF165,
128,129
 was compared to the commercially available pVAX1 vector (Invitrogen, 
CA, USA). The third full-length plasmid construct investigated was the MC-parental plasmid. 
As this study was performed using the first generation Chen system, the parental plasmid was 
rather large, over 9 kbp. It was evident from the in vitro studies in a human cell line that the 
large size of the parental plasmid impairs the efficiency of the vector. However, the 
phVEGF165 vector was much more efficient than the pVAX, despite being almost twice the 
size. The MC vector, containing the same cassette as the phVEGF165 construct but 
encompassing only 2.4 kbp, surpassed even the highly expressing phVEGF165 construct. 
Thus, for the in vivo experiments, only these two constructs where used. The constructs were 
compared in heart and in skeletal muscle in equimolar and equal weight doses, delivered by 
direct intramuscular injection of naked DNA. In heart, the expression is equal when the same 
molar dose is used, both after 24 hours and after seven days. When injecting the same weight 
dose of MC and plasmid, the hVEGF expression is higher in the MC treated hearts due to the 
increased dose of therapeutic DNA. In skeletal muscle, the MC vector has a slightly elevated 
expression when compared to an equimolar dose of plasmid, but only an equal weight dose 
gives a significant difference after seven days. It is possible that the difference in expression 
would become more pronounced over time. However, as the method used to detect hVEGF in 
vivo demands sacrifice of the animals, hVEGF is not the optimal reporter to characterize 
expression of MC as compared to plasmid over time. Lijkwan et al. use luciferase as a 
reporter gene to compare expression from equimolar treatment with MC and a plasmid 
construct in mouse skeletal muscle.
64
 They report significantly higher expression from the 
MC for up to 28 days. However, there is barely any expression from the plasmid at the dose 
given. Huang et al. do a similar comparison in murine heart.
61
 In heart, the MC had a higher 
expression than the plasmid and although the expression did drop, luciferase was detectable 
for 90 days. When using the therapeutically more relevant HIF-1α protein, Huang et al. were 
able to detect significant expression from the MC vector 14 days after treatment, with levels 
more than twice those of the plasmid construct.  
A difference between the studies in paper I and those of Lijkwan et al.  and Huang et al., 
apart from different reporter genes, is that they both utilized the ubiquitin promoter to drive 
the protein expression, whereas our constructs contain the CMV promoter. The importance of 
promoter is highlighted in another paper comparing MC and plasmid for hVEGF expression, 
where Chang et al. studies three different promoters, among them CMV, and report quite 
different effects in vitro and in vivo two days after treatment.
59
 Gill et al. investigate different 
viral promoters, such as CMV, and compare their gene expression profile to the human 
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ubiquitin C and elongation factor 1alpha promoters in lung.
130
 The ubiquitin promoter had a 
far more long-term expression than the CMV promoter, which drops to 10% of initial 
expression level after two weeks. This drop in expression was not correlated with any loss of 
vector. Riu et al. aim to shed light on the mechanism of plasmid silencing by studying histone 
modification in plasmids and MC vectors, and also compare different promoters in liver.
19
 
When studying the Rous sarcoma virus promoter, a prominent difference in the patterns 
between the MC and the full-length plasmid was observed, indicating a formation and 
spreading of heterochromatin in the plasmid. The pattern of histone modifications on the MC 
DNA was consistent with euchromatin, which correlates with the prolonged transgene 
expression in liver. These differences in histone modifications between MC and plasmid were 
not seen after 24 hours or seven days, only after several weeks. This is of interest when 
looking at paper I and the Chang et al. results; chromatin changes would not yet affect the 
expression levels at the time points studied. When Riu et al. characterize the ubiquitin C 
promoter, the chromatin patterns in the plasmid and MC vectors are more alike also over 
time, and so is the expression profile. They hypothesize that this promoter contains several 
recognition sites associated with transcription factors that are able to maintain the original 
euchromatin histone modification patterns. That the design of the gene expression cassette 
highly influences the levels of gene expression is also evident in paper I, in the comparison 
between the pVAX and the phVEGFI165 vectors which both contain the CMV promoter but 
with different enhancer elements. Regarding vector type, the smaller size, the absence of 
antibiotics resistance gene  and a lower CpG content make the MC a useful and appealing 
alternative for future cardiovascular gene therapy treatments even when the expression levels 
per construct is comparable to that of the plasmid. 
4.4 SNRNA EXPRESSION FROM MC IN MUSCLE  
In paper II, we demonstrated that the MC can be used as a vector for delivery of a splice 
correcting cassette, and that it had a higher and more robust effect than a plasmid construct in 
liver. However, the study utilized an artificial luciferase system and an experimental setup 
using co-injections of reporter plasmid and splice-correcting construct in vivo. DMD is a 
more clinically relevant system, as many mutations causing the loss of dystrophin in DMD 
can potentially be rescued by inducing skipping of mutated exons in the pre-mRNA to restore 
the reading frame. The induced exon-skipping leads to production of a shortened, but 
functional, protein and the phenotype will be similar to Becker Muscular Dystrophy – a much 
less severe illness than DMD.
131
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In paper III, the miMC was assayed as vector for a splice-switching snRNA targeting the in 
the mdx mouse model. The mdx mouse has a point mutation in exon 23 of the mouse 
dystrophin gene, which introduces a premature stop codon that causes the absence of full-
length dystrophin. A miMC containing a U7 splice correcting cassette previously used by 
Goyenvalle et al.
93
, and which induces skipping of exon 23 was cloned. The miMC was 
tested in vitro in mouse H2K mdx muscle cells as well as in the live animal. In vitro, the 
miMC outperformed a plasmid construct carrying the same cassette by far. Already at the 
lowest dose, 0.5 µg miMC, the miMC induced splice-switching, whereas using the same 
molar dose of plasmid had no effect. In a comparison using 4 µg miMC and the same weight 
amount of plasmid, the miMC induced ten times higher correction than the plasmid. It is 
possible that a plasmid dose corresponding to the molar amount of cassettes in 4 µg miMC 
could induce decent splicing, but the levels would most certainly be toxic for the cells, as the 
plasmid is nearly six times larger than the miMC. In the in vivo experiments, the miMC was 
first delivered by intramuscular injections into the TA of the mdx mice. After two weeks, the 
miMC had induced a significant increase in dystrophin levels in the treated muscle. These 
experiments show that it is feasible to use the miMC as a vector for inducing splice-switching 
of dystrophin mRNA and restoration of protein production in muscle.  
However, as the levels of dystrophin were modest after naked injection, we also assayed two 
different physical methods to increase miMC delivery. High volume perfusion of mdx mouse 
hind limb did not induce any splice-switching that was detectable with end point RT-PCR 
four weeks after treatment. Electroporation of the muscle after injection of the miMC did 
induce expression of the splice-switching snRNA quantifiable by qRT-PCR, and rescue of 
protein production detectable by immunohistology two weeks after treatment. However, the 
protein levels are in pair with the amounts achieved by intramuscular injection alone. These 
two results both highlight the question of timing of the analysis. Tennyson et al. report that 
the dystrophin is a low abundance transcript with 5-10 mRNA copies per cell, and that the 
ratio of nascent to mature dystrophin transcript indicates that dystrophin synthesis may not be 
at steady state in the adult skeletal muscle.
132
 Spitali et al. describe that the mRNA transcript 
levels are not constant across the gene, perhaps because of incomplete transcription.
133
 This 
can influence the amount of mRNA available for splice-switching and subsequent protein 
production. It is thus possible that two weeks is too short to see the effect of an increased 
delivery. This could explain our data as well as the observation from Goyenvalle et al. when 
they study AAV-vectors for delivery of the U7 construct inducing splice-switching of 
dystrophin. They describe little effect on dystrophin levels after two weeks, but a pronounced 
skipping and protein restoration after four to eight weeks.
93
 However, they also assay the 
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expression of U7snRNA by end point PCR, and although no quantitative values are reported 
they show expression from the constructs already after two weeks. This is in accordance with 
our results, and indicates that two weeks is not enough time for the splice-switched mRNA 
and rescued dystrophin protein to accumulate. On the other hand, the same group show in 
another study that if the dystrophin rescue is suboptimal, a splice-switching AAV vector can 
be lost already after three weeks.
134
 They attribute this to the cycles of degeneration and 
regeneration of muscles associated with DMD. This suggests that even if the miMC was 
functional and had a slight effect it could have been lost at the time of assay four weeks after 
treatment if the delivery using high volume perfusion was poor. These results highlight the 
need for efficient vector delivery. Future experiments will tell if delivery miMC with 
electroporation will result in high enough expression and protein rescue to overcome the loss 
of transfected cells through degeneration.   
The MC could be a more optimal vector than the conventional plasmid for delivery with 
electroporation. As discussed before it seems that the CpG content of the vector affects the 
tissue response to the electroporation in muscle.
18
 As the MC is devoid of bacterial 
sequences, the CpG content will be reduced compared to a full length plasmid carrying the 
same cassette. A lower amount of CpGs would lead to a lower inflammatory response to the 
electroporation treatment, and could thus result in a more stable gene expression. The reduced 
size resulting from the removal of bacterial sequences could also enhance the delivery, as 
studies have shown that the efficiency of electroporation correlates with the size of the 
plasmid DNA constructs, with large size hampering effective gene transfer.
32
 Chabot et al. 
have studied the mechanism of electroporation of MC in vitro using a GFP reporter gene, and 
note that the MC had an increased interaction with the cell membrane, as compared to a 
conventional plasmid vector, and hypothesises that this could be due to the smaller size of the 
MC vector. 
87
 Their study also reports a higher and more sustained expression in vivo with the 
MC vector after electroporation to muscle.  Thus, as it is even smaller than the MC vector 
used by Chabot et al., there is hope for the miMC.  
5 CONCLUSION AND FUTURE PERSPECTIVES 
The work presented in this thesis has aimed to investigate the possibilities to use the MC as a 
vector for gene transfer into muscle. I have studied how the size of the MC vector affects 
transfer and expression efficiency, as well as other aspects such as robustness. The vector has 
been used for expression of both a therapeutic protein and a splice-switching snRNA in 
muscle.  
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From the experimental data which are the basis for this thesis, as well as from the related 
literature, it is evident that the MC has certain advantages as well as limitations. Table 2, 
adapted from Stenler et al.,
135
 summarizes some of the published advantages of the MC 
vector, with exemplifying references. Due to its smaller size and lack of untranscribed 
bacterial sequences, it has a prolonged and more stable expression than the conventional 
plasmid. Furthermore, the vector does not contain any antibiotics resistance genes, which 
limits the risk of spreading of these genes. Optimizing the regulatory sequences in the 
expression cassette will affect the expression profile and can increase the effect even further. 
Any further loss of expression over time can be overcome by repeated treatment, which has 
been shown to be quite well tolerated when using the MC in mouse skeletal muscle.
61
 The 
smaller size also allows for a higher effective dose, and has been shown to be beneficial in 
gene transfer, both when using chemical and physical methods.  
5.1 DELIVERY METHODS 
Efficient delivery remains one of the main difficulties when using nonviral vectors, and the 
MC is no exception. Our work and others indicate that electroporation can be a suitable 
method to enhance delivery of the MC into muscle. The vector itself could be further 
optimized for muscular delivery by electroporation. A sequence that has been shown to 
increase gene expression in smooth muscle after electroporation is a region of the smooth 
muscle γ-actin promoter.136 It contains a tissue specific transcription factor binding site which 
drives nuclear accumulation of the vector. Hydrodynamic perfusion of hind limb is another 
method that has been used successfully by others for delivery to muscle of viral vectors and 
Effect of MC Assay Reference 
Efficient immune 
response 
HIV-1 DNA vaccination 
in mouse muscle 
Wang et al. 2014 
Prolonged expression Human factor IX and 
alpha1-antitrypsin in 
mouse liver 
Chen et al. 2003 
Enhanced serum 
stability 
Incubation in human 
serum 
Zhao et al. 2010 
Increased shearing 
resistance 
Sonication and 
nebulization 
Cantanese et al. 
2012 
Robust supercoiled 
fraction 
Biojection through 
mouse hide 
Stenler et al. 2014 
Table 2. MC versus plasmid in biological assays. Comparison of different properties of the 
MC and plasmid, with selected references. Modified from Stenler et al.
135
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ASO as well as for plasmids, although it did not show increased gene delivery in our hands. 
However, neither hydrodynamics nor electroporation would be a realistic tool for delivery to 
every muscle in the body, as would be needed for efficient treatment of many muscular 
diseases, such as DMD. These methods would be more suitable for delivery of vectors for 
treatment of e.g. cardiovascular diseases, such as cardiac or peripheral limb ischemia, where 
it would be possible to target the affected muscles or limbs only. An efficiently transfected 
muscle could in principle also be used as production site for a secreted therapeutic protein 
that could have its target elsewhere in the body. As the skeletal muscle cells are not dividing, 
the vector would be present in the tissue for a long time.  
Hydrodynamics has also been used in several studies for delivery of MC to the liver of mice, 
and has shown a higher and more robust expression as compared to plasmid. However, for 
the method to be safe for humans there is a need for optimization of e.g. injection volumes 
and techniques for clamping of vessels to affect only parts of the liver. Ultrasound is another 
physical method that has been used for gene delivery of MC vectors, targeting the salivary 
glands of mice.
137
 The study reports that the MC vector had an increased expression of 
luciferase as compared to a conventional plasmid. Furthermore, the authors analyze the 
proteomic profile of the gland and see that plasmid caused a change of protein content, 
especially in pathways associated with immunity, cellular stress, and morphogenesis. This 
was seen to a much smaller extent when using the MC as gene delivery vector. The plasmid 
backbone induces an immunological response similar to that seen when using viral vectors. 
Thus the MC vector does not only enable a higher expression, but is also less toxic than a 
full-length plasmid vector. 
Chemical delivery is another approach to achieve more efficient delivery, which is sorely 
needed for full body muscular treatments using nonviral vectors. Chemical delivery refers to 
the use of different carrier lipids or peptides to condense and protect the DNA and enhance 
the cellular uptake. There are numerous studies on optimizing the chemistry of the carrier, as 
well as coupling it to signal moieties for improved uptake and intracellular traffic. These can 
be nuclear localization signals or cell binding ligands. Such ligands can also promote 
targeting of the vector to a given organ. The use of cell penetrating peptides, covalently or 
non-covalently attached to the cargo, can facilitate entry into cells. As an example of how 
these methods can be combined, Ko et al. report that targeted gene delivery to ischemic 
myocardium by intravenous injection in rats is enhanced when pDNA and lipid complexes 
are modified with cell penetrating peptides and a monoclonal antibody specific for cardiac 
myosin.
138
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5.2 DNA VACCINATION 
With the limitations of delivery efficiency, the MC might be more suitable for use when only 
local expression is needed. One such situation is DNA vaccination, where the antigen is 
commonly delivered to a small area intradermally or intramusculary. Electroporation has 
been shown to be an efficient delivery method for eliciting strong immune responses in 
humans.
139
 Both the increased DNA uptake and the local tissue damage acting as an adjuvant 
is believed to improve the immunization. As discussed previously, the MC could be a more 
optimal vector for delivery with electroporation than a conventional plasmid due to its 
smaller size. Another benefit of the smaller size is the increased therapeutic dose per µg DNA 
when using MCs as compared to normal plasmids. This is of importance as high local 
transgene expression is crucial for a good immune response. However, one feature of plasmid 
DNA itself that is thought to induce an immune response is the unmetylated CpGs discussed 
earlier. It has been shown that a CpG rich sequence can act as adjuvant for vaccines. An MC 
vector for DNA vaccination will have less CpGs than a conventional plasmid, as it is shorter. 
However, optimized CpG sequences could be cloned into to the MC cassette. Some studies, 
e.g. Coban et al, have shown that inclusion of certain optimized CpG sequences in a plasmid 
enhances the immune response in mice.
140
 These sequences are only between 30 and 50 bp so 
the resulting MC would still be considerably smaller than a conventional plasmid. 
Alternatively, the MC could be delivered together with synthetic CpG oligonucleotides. Co-
administering CpG oligonucleotides with a variety of vaccine agents has improved the 
humoral and cellular immune responses.
141
 For DNA vaccine purposes, it could very well be 
an advantage to not have the adjuvant covalently attached to the DNA sequence from which 
the antigen is to be expressed.  
5.3 EX VIVO THERAPIES 
Ex vivo therapy can be seen as an extreme example of local therapeutic gene expression. Ex 
vivo treatment aims to remove cells from a patient, modify them in the laboratory and then 
return the modified cells to the patient where they affect the disease. In this case, it could be 
beneficial to be able to use a high therapeutic dose of a non-integrating vector devoid of any 
resistance genes, which could be transferred back to the patient. Evans and Hyde review 
several gene therapy approaches to regenerate the musculoskeletal system, among them ex 
vivo strategies mainly using viral vectors.
142
 Usas et al.
143
 study muscle derived stem cells 
and the possibility to modify them ex vivo, e.g. using retroviral vectors to enhance bone 
formation; this naturally with a risk of introducing cells harbouring an insertional mutation. 
They also modified the stem cells with a combination of growth factors, such as VEGF, 
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which enhanced bone generation. When considering using growth factors, the prolonged, but 
still in the end transient, expression associated with episomal vectors such as the MC could 
be beneficial, as growth factors are known to be involved in several steps of cancer 
development.
144
 Indeed, Sheyn et al. use adipose tissue-derived stem cells modified ex vivo 
with a plasmid vector to enhance bone formation and spinal fusion.
145
 They conclude that the 
nonviral gene delivery method used to genetically engineer the stem cells ex vivo is safe and 
transient, limiting overexpression of the osteogenic gene to a period of a few weeks. Also the 
MC vector has been used ex vivo in human adipose-derived stromal cells, to induce a 
transient overexpression of the Bcl-2 prosurvival protein.
75
 This enhanced cell survival and 
bone formation upon implantation into a mouse model, and expression was seen for up to 
four weeks. 
5.4 SUMMARY 
The MC is one of the safest vectors available for gene therapy. It demonstrates a more stable 
expression as compared to conventional plasmids, and its smaller size allows for a high dose 
and possibly more efficient transfection. It can be used in muscle both to express therapeutic 
proteins and for RNA therapeutics. Even though the expression is prolonged as compared to 
conventional plasmids, and can be further improved by designing the regulatory elements in 
the vector, the expression will be less stable than for integrating vectors. For some uses, 
transient expression is not necessarily a disadvantage. However, for use where systemic 
treatment is need, delivery must be enhanced by the use of chemical or physical transfection 
methods. Thus, the vector might be more suitable for treatments where only local expression 
is needed, such as single organ treatment, DNA vaccination or ex vivo treatment.  
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